76
Participants
Start Date
April 30, 2016
Primary Completion Date
May 18, 2021
Study Completion Date
August 11, 2023
certolizumab
Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
Stress myocardial perfusion PET
We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
Brigham and Women's Hospital, Boston
Brigham and Women's Hospital
OTHER